WO2009124226A3 - Gelsolin uses in neurological disorders - Google Patents

Gelsolin uses in neurological disorders Download PDF

Info

Publication number
WO2009124226A3
WO2009124226A3 PCT/US2009/039382 US2009039382W WO2009124226A3 WO 2009124226 A3 WO2009124226 A3 WO 2009124226A3 US 2009039382 W US2009039382 W US 2009039382W WO 2009124226 A3 WO2009124226 A3 WO 2009124226A3
Authority
WO
WIPO (PCT)
Prior art keywords
gelsolin
neurological disorders
prognosis
diagnosis
directed
Prior art date
Application number
PCT/US2009/039382
Other languages
French (fr)
Other versions
WO2009124226A2 (en
Inventor
Robert Bucki
Paul Janmey
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of WO2009124226A2 publication Critical patent/WO2009124226A2/en
Publication of WO2009124226A3 publication Critical patent/WO2009124226A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to methods of diagnosis, prognosis, and treatment of a neurological disorder. Specifically, the invention is directed to methods of diagnosis, prognosis, and treatment of a neurological disorder based on measuring changes in the level of gelsolin in cerebrospinal fluid. The invention is also directed to a method for treating, inhibiting, or suppressing a bacterial lipoteichoic acid (LTA)-induced pathogenesis in a subject by contacting the subject with a therapeutically effective amount of gelsolin.
PCT/US2009/039382 2008-04-03 2009-04-03 Gelsolin uses in neurological disorders WO2009124226A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6493508P 2008-04-03 2008-04-03
US61/064,935 2008-04-03

Publications (2)

Publication Number Publication Date
WO2009124226A2 WO2009124226A2 (en) 2009-10-08
WO2009124226A3 true WO2009124226A3 (en) 2010-01-07

Family

ID=41136117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/039382 WO2009124226A2 (en) 2008-04-03 2009-04-03 Gelsolin uses in neurological disorders

Country Status (1)

Country Link
WO (1) WO2009124226A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106577A2 (en) * 2006-03-15 2007-09-20 The Brigham And Women's Hospital, Inc. Gelsolin in the treatment and diagnosis of neurological disease
US20070238668A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070238668A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
WO2007106577A2 (en) * 2006-03-15 2007-09-20 The Brigham And Women's Hospital, Inc. Gelsolin in the treatment and diagnosis of neurological disease

Also Published As

Publication number Publication date
WO2009124226A2 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
WO2008152656A3 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
WO2009109908A8 (en) Methods of treating inflammatory pain
WO2011031786A3 (en) Compositions and methods for diagnosing autism spectrum disorders
WO2009109911A8 (en) Methods of treating chronic pain
WO2013003350A3 (en) Microrna biomarkers indicative of alzheimer's disease
WO2008097277A3 (en) Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
WO2010006609A8 (en) System for regulating intracranial pressure
WO2009043051A3 (en) Cd23 binding molecules and methods of use thereof
WO2010117829A3 (en) Differentially expressed micrornas as biomarkers for the diagnosis and treatment of sjögren's syndrome
WO2012051996A3 (en) Method and device for the measurement and the elimination of system changes in a device for the treatment of blood
PL1974210T3 (en) Method for diagnosing polycystic kidney disease
WO2010062377A3 (en) Methods and compositions for the detection and treatment of preeclampsia
WO2012058268A3 (en) Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
WO2011028912A3 (en) A biomarker for neurodegeneration in neurological disease
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma
WO2005093413A3 (en) Diagnosis and treatment of preeclampsia
WO2006138372A3 (en) Methods and reagents for the treatment of inflammatory disorders
WO2006121995A3 (en) Methods for treating nephrolithiasis
GB0808834D0 (en) Biomarkers for depression
GB0808832D0 (en) Biomarkers for depression
WO2009098355A8 (en) Novel use of probiotics
WO2009124226A3 (en) Gelsolin uses in neurological disorders
WO2011052906A3 (en) Use of eif3m for the diagnosis and treatment of cancer
IL210382A0 (en) Immunoassay for detection of neurotoxic amino acid associated with neurological disorders
WO2011005581A3 (en) Methods of increasing neuronal differntiation using antibodies to lysophoshatidic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09726634

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09726634

Country of ref document: EP

Kind code of ref document: A2